Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC 6bK TFA | 1774353-12-6 | 99.7% | 871.94 | 10 MG
6bK TFA is a potent and selective inhibitor of insulin degrading enzyme (IDE) with an IC50 value of 50 nM. It increases circulating insulin in high-fat-fed mice and enhances glucose tolerance to oral glucose, notably to a greater extent in high-fat-fed mice. This product is suitable for type 2 diabetes research.
- Potent and selective inhibitor of insulin degrading enzyme (IDE)
- Increases circulating insulin in high-fat-fed mice
- Enhances glucose tolerance to oral glucose
- Suitable for type 2 diabetes research
- For research use only
Medchemexpress LLC Relamorelin (TFA) | 2863659-22-5 | 99.8% | 905.00 | 50 MG
Relamorelin (TFA) | 2863659-22-5 | 99.8% | 905.00 | 50 MG
Medchemexpress LLC F11R peptide TFA | 97.6% | 1459.58 | 5 MG
F11R peptide TFA is an F11 receptor molecule that inhibits anti-F11R antibody-induced platelet aggregation and the adhesion of platelets to cytokine (TNFα and INF-γ)-inflamed endothelial cells. It can be used for research of atherosclerotic plaques and associated thrombotic disease.
- Inhibits anti-F11R antibody-induced platelet aggregation.
- Inhibits the adhesion of platelets to cytokine (TNFα and INF-γ)-inflamed endothelial cells.
Medchemexpress LLC DPC-AJ1951 (TFA) | 99.4% | 1666.99 (free base) | 1 MG
DPC-AJ1951 TFA is a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR). Its activity has been characterized in ex vivo and in vivo assays of bone resorption. In vitro, it induces intracellular Ca2+ mobilization in HEK 293 cells transfected with the human PPR.
- Acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR)
- Activity characterized in ex vivo and in vivo assays of bone resorption
- Induces intracellular Ca2+ mobilization in HEK 293 cells transfected with the human PPR
- 14 amino acid peptide
Medchemexpress LLC Ant308 (TFA) | 99.6% | 3467.10 (free base) | 1 MG
ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist that significantly enhances the activation and proliferation of T cells. It inhibits the migration and metastasis and induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling. This compound reduces the expression of MCAM and N-cadherin, making it suitable for studies on acute myeloid leukemia (AML) and uveal melanoma (UVM).
- Vasoactive intestinal polypeptide (VIP receptor) antagonist
- Enhances T cell activation and proliferation
- Inhibits migration and metastasis of melanoma cells
- Induces apoptosis in melanoma tumor cells
- Inhibits VIP-VPAC2 signaling
- Reduces MCAM and N-cadherin expression
- Useful for acute myeloid leukemia (AML) research
- Useful for uveal melanoma (UVM) research
Medchemexpress LLC [D-Lys6]-LH-RH TFA | 1253.41 (free base) | 50 MG
[D-Lys6]-LH-RH TFA is a Luteinizing-hormone-releasing hormone (LHRH) analogue that acts as a GnRH receptor agonist. It is used in research, including studies on the inhibition of growth of experimental prostate cancer.
- Luteinizing-hormone-releasing hormone (LHRH) analogue
- Acts as a GnRH receptor agonist
- Used in research, including studies on the inhibition of growth of experimental prostate cancer
Medchemexpress LLC D-GsMTx4 TFA | 99.9% | 4095.84 | 100 UG
D-GsMTx4 TFA is a spider peptide and the D enantiomer of GsMTx4. It inhibits the mechanosensitive ion channel Piezo2, [Ca2+]i elevation, and mTOR and PI3K-Akt signaling pathways. This compound can inhibit mechanical allodynia and thermal hyperalgesia.
- Inhibits the mechanosensitive ion channel Piezo2.
- Inhibits intracellular calcium elevation.
- Inhibits mTOR and PI3K-Akt signaling pathways.
- Can be used in research related to mechanical stress.
- Useful for studies on chronic pain and idiopathic pulmonary fibrosis.
Medchemexpress LLC Gln-AMS TFA | 99.9% | 588.47 | 100 MG
Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor, specifically inhibiting glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM.
- Inhibits glutaminyl-tRNA synthetase (GlnRS)
- Type Ia aminoacyl-tRNA synthetase (AARS) inhibitor
- White to off-white solid
- Purity of 99.85%
- Soluble in DMSO at 100 mg/mL
- Store at -20°C under nitrogen
![Medchemexpress LLC Coenzyme A S-[2-[[(5S)-5-(acetylamino)-6-amino-6-oxohexyl]amino]-2-oxoethyl] trifluoroacetic acid | 00-00-0 | 98.5% | C33H54F3N10O21P3S | 10MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000261718.png-250.jpg)
Medchemexpress LLC Coenzyme A S-[2-[[(5S)-5-(acetylamino)-6-amino-6-oxohexyl]amino]-2-oxoethyl] trifluoroacetic acid | 00-00-0 | 98.5% | C33H54F3N10O21P3S | 10MG
Lys-CoA TFA (Lys-coenzyme A) is a selective inhibitor of the p300 histone acetyltransferase used as a biochemical tool to study p300-mediated acetylation and transcriptional regulation. It exhibits nanomolar potency against p300 and marked selectivity over related acetyltransferases, and is supplied as a high-purity solid for laboratory research.
- Selective p300 HAT inhibitor with p300 IC50 50-500 nM
- Greater than 100-fold selectivity over PCAF
- High purity (98.5%) for research applications
- Solid, white to off-white physical form
- Recommended sealed storage at -20°C; in solvent store at -80°C for long-term
Medchemexpress LLC Wrwyar-NH2 TFA | 70.8% | 936.07 | 5 MG
Wrwyar-NH2 TFA is a control peptide primarily targeting DNA/RNA synthesis. It plays a role in the Cell Cycle/DNA Damage pathway. This product is intended for research use only and has not been fully validated for medical applications.
- Control peptide
- Targets DNA/RNA synthesis
- Involved in cell cycle/DNA damage pathway
- For research use only
Medchemexpress LLC FRETS-VWF73 (TFA) | 96.8% | 9340.61 | 500 UG
FRETS-VWF73 (TFA) is a 73-amino-acid peptide that serves as a fluorogenic substrate for the ADAMTS13 assay. This peptide is utilized as a predictive tool for thrombotic thrombocytopenic purpura, offering a valuable resource for research and diagnostic applications.
- 73-amino-acid peptide
- Fluorogenic substrate for ADAMTS13 assay
- Used as a predictive tool for thrombotic thrombocytopenic purpura
- Excitation at 340 nm; emission at 450 nm
Medchemexpress LLC Huwentoxin-IV TFA | 526224-73-7 | 4106.78 | 500 UG
Huwentoxin-IV is a potent and selective sodium channel blocker. It inhibits neuronal Nav1.7, Nav1.2, Nav1.3, and Nav1.4, with preferential blocking of peripheral nerve subtype Nav1.7. This compound has also demonstrated analgesic effects in animal models of inflammatory and neuropathic pain.
- Potent and selective sodium channel blocker
- Inhibits neuronal Nav1.7, Nav1.2, Nav1.3, and Nav1.4
- Preferentially blocks peripheral nerve subtype Nav1.7
- Binds to neurotoxin receptor site 4
- Analgesic effects in animal models of inflammatory and neuropathic pain
Medchemexpress LLC Astressin 2B TFA | 98.5% | 4041.69 | 1 MG
Astressin 2B TFA is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist. It blocks protective effects mediated by CRFR2, exacerbating indomethacin-induced hemorrhagic intestinal injury in rats. This compound reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion, and upregulation of inflammatory mediators. It is an important tool molecule for investigating intestinal protective mechanisms of CRFR2.
- Highly selective CRFR2 antagonist
- Blocks anxiogenic effect of Urocortin 2
- Attenuates stress-induced anxiety-related behaviors
- Exacerbates intestinal epithelial damage in specific models
- Important tool for investigating intestinal protective mechanisms of CRFR2
Medchemexpress LLC Cef20 (Tfa) | 99.3% | 1057.19 | 25 MG
CEF20 TFA is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503).
- High purity of 99.31%
- Molecular weight of 1057.19
- Solid appearance
- White to off-white color
- Sequence: Asn-Leu-Val-Pro-Met-Val-Ala-Thr-Val (NLVPMVATV)
- Soluble in DMSO
- Store in sealed container, away from moisture
- Powder storage: -80°C for 2 years, -20°C for 1 year
- Storage in solvent: -80°C for 6 months, -20°C for 1 month
Apexbio Technology LLC SCH772984 TFA 942183-80-4 (free base) 5mg
SCH772984 TFA is a small-molecule inhibitor targeting extracellular signal-regulated kinase 1/2 (ERK1/2) It is designed to inhibit ERK catalytic activity thereby blocking phosphorylation of downstream substrates and regulating the RAS-RAF-MEK-ERK signaling pathway SCH772984 TFA exerts its biological activity primarily through direct interaction with ERK1/2 acting as an ATP-competitive inhibitor Based on these pharmacological properties SCH772984 TFA holds research potential in studies examining ERK signaling s role in oncogenic pathway activation tumor cell growth survival mechanisms and resistance phenomena in various cancer models